Your patients count!





Thank you for participating in the Community Counts Registry. We've **learned so much** about bleeding disorders in **women and girls*** from you and your patients. **Your patients and your data count!**


*Community Counts data are recorded by sex assigned at birth and information presented here includes all people who have shared biological risk factors for bleeding disorders due to birth sex

7,072 Registry participants (28%) are **women and girls**

Data as of 5/1/2024

Women and girls can present differently for a bleeding disorder diagnosis than men and boys.

52% of women and girls received treatment for a first bleed at ages 6-19 years old, compared to 21% of men and boys in this age group**



**among patients with a documented age at first bleeding treatment


65% of women and girls in the Registry have Von Willebrand Disease, compared to only 12% of men and boys. Other Bleeding

				Disorders (20%)
Diagnosis	4,536 women and	l girls	I,097	1,394
	Von Willebrand (65%)	Hemophilia (15%)		



Scan to read a **journal article** on bleeding disorders in women and girls Over 10 years, the number of **female patients** seen by hemophilia treatment centers^ **nearly doubled** and the percentage of female patients **increased from 35% to 42%**. Having more women and girls in the Registry will improve our understanding of bleeding disorders in this population.

^ Data source: HTC Population Profile, September 2023



Help us spread the message!

The National Bleeding Disorder Foundation's **"Better You Know"** program was developed to raise awareness of bleeding disorders among women and girls who may experience bleeding symptoms but have not yet been diagnosed and to increase awareness among nonhematology healthcare providers.

Help us get the word out - women and girls have bleeding disorders and, for some women, heavy periods can be an important clue for earlier diagnosis and better care.



Scan to learn about **Better You Know**



Community Counts is a project funded by the Centers for Disease Control and Prevention (CDC) through a cooperative agreement NU27DD000020 awarded to the American Thrombosis and Hemostasis Network (ATHN) in partnership with the U.S. Hemophilia Treatment Center Network (USHTCN). The contents are those of the author(s) and do not necessarily represent the official views of, nor endorsement, by CDC/HHS or the U.S. Government.